Where did platelets go in 2012? A survey of platelet transfusion practice in the North of England

Charlton, Amanda; Wallis, Jonathan P.; Robertson, James; Watson, Douglas; Iqbal, Atif; Tinegate, Hazel

doi:10.1111/tme.12126

Cited by 44 publications

(41 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The majority of platelet transfusions are given prophylactically to thrombocytopenic hematooncology patients [183]. As such, a longer lifespan in the circulation is desirable, and cold storage of platelets ceased, with adoption of storage at RT (20–24°C).…”

Section: Quality Of Platelet Concentratesmentioning

confidence: 99%

Quality Assessment of Established and Emerging Blood Components for Transfusion

Acker

Marks

Sheffield

2016

Journal of Blood Transfusion

View full text Add to dashboard Cite

Blood is donated either as whole blood, with subsequent component processing, or through the use of apheresis devices that extract one or more components and return the rest of the donation to the donor. Blood component therapy supplanted whole blood transfusion in industrialized countries in the middle of the twentieth century and remains the standard of care for the majority of patients receiving a transfusion. Traditionally, blood has been processed into three main blood products: red blood cell concentrates; platelet concentrates; and transfusable plasma. Ensuring that these products are of high quality and that they deliver their intended benefits to patients throughout their shelf-life is a complex task. Further complexity has been added with the development of products stored under nonstandard conditions or subjected to additional manufacturing steps (e.g., cryopreserved platelets, irradiated red cells, and lyophilized plasma). Here we review established and emerging methodologies for assessing blood product quality and address controversies and uncertainties in this thriving and active field of investigation.

show abstract

Section: Quality Of Platelet Concentratesmentioning

confidence: 99%

Quality Assessment of Established and Emerging Blood Components for Transfusion

Acker

Marks

Sheffield

2016

Journal of Blood Transfusion

View full text Add to dashboard Cite

show abstract

“…Fibrinogen concentrate Larsen et al (2013) In clinical use largely outside the setting of thrombocytopenia. However, many audits have documented widespread use of platelet transfusions pre-procedure (Charlton et al, 2014;Qureshi et al, 2007). RCT evidence in other settings.…”

Section: No Platelet Transfusionmentioning

confidence: 99%

Alternatives to allogeneic platelet transfusion

et al. 2016

View full text Add to dashboard Cite

Allogeneic platelet transfusions are widely used for the prevention and treatment of bleeding in thrombocytopenia. Recent evidence suggests platelet transfusions have limited efficacy and are associated with uncertain immunomodulatory risks and concerns about viral or bacterial transmission. Alternatives to transfusion are a well-recognised tenet of Patient Blood Management, but there has been less focus on different strategies to reduce bleeding risk by comparison to platelet transfusion. Direct alternatives to platelet transfusion include agents to stimulate endogenous platelet production (thrombopoietin mimetics), optimising platelet adhesion to endothelium by treating anaemia or increasing von Willebrand factor levels (desmopressin), increasing formation of cross-linked fibrinogen (activated recombinant factor VII, fibrinogen concentrate or recombinant factor XIII), decreasing fibrinolysis (tranexamic acid or epsilon aminocaproic acid) or using artificial or modified platelets (cryopreserved platelets, lyophilised platelets, haemostatic particles, liposomes, engineered nanoparticles or infusible platelet membranes). The evidence base to support the use of these alternatives is variable, but an area of active research. Much of the current randomised controlled trial focus is on evaluation of the use of thrombopoietin mimetics and anti-fibrinolytics. It is also recognised that one alternative strategy to platelet transfusion is choosing not to transfuse at all.

show abstract

“…The majority of platelet concentrates are prescribed to haematology and oncology patients either as adjunctive treatment of hypoproliferative thrombocytopenia secondary to underlying malignancy or bone marrow failure, or as a result of treatments including chemotherapy, radiotherapy and haematopoietic stem cell transplantation (HSCT). Nearly 70% of patients with haematological malignancy receiving chemotherapy or HSCT will have clinically significant bleeding (WHO grade 2 or higher) and just under 10% will have major or life‐threatening bleeding .…”

Section: Clinical Contextsmentioning

confidence: 99%

An update on indications for platelet transfusion

Wood

Crighton

Estcourt

et al. 2016

ISBT Science Series

View full text Add to dashboard Cite

Platelets are very commonly prescribed blood components, and in many settings, their use is increasing. They may be used either prophylactically (to attempt to prevent bleeding) or therapeutically (to treat bleeding when it occurs). This review provides a summary of the major clinical settings in which platelet transfusions are currently used. Most platelet transfusions are provided prophylactically to thrombocytopenic haematology/oncology patients, although bleeding risks and rates appear to vary substantially between individual patients. Other contexts include major haemorrhage, surgery and invasive procedures, and patients in critical care and neonatal intensive care. Since platelet transfusions carry risks and costs, and evidence of benefit for platelet transfusion in many clinical settings is not yet available, additional clinical studies to establish the utility of platelet transfusions and other interventions to prevent or manage bleeding are needed.

show abstract

Where did platelets go in 2012? A survey of platelet transfusion practice in the North of England

Abstract: The commonest indication for platelet use, where reinforcement of guidelines will be productive, is prophylaxis in haematological disease. Use of platelets in cardiac surgery is also worthy of close scrutiny.

Cited by 44 publications

References 12 publications

Quality Assessment of Established and Emerging Blood Components for Transfusion

Quality Assessment of Established and Emerging Blood Components for Transfusion

Alternatives to allogeneic platelet transfusion

An update on indications for platelet transfusion

Contact Info

Product

Resources

About